Targeted intestinal release non-denatured II-type collagen-hydrophobic phytochemical-chondroitin sulfate compound and preparation method thereof
By forming a non-denaturated type II collagen-hydrophobic phytochemical-chondroitin sulfate ternary complex, the formation of a tight complex under acidic conditions is solved by using electrostatic interactions to form a tight complex, which is solved by degrading hydrophobic phytochemicals during gastric digestion. The problem has achieved targeted intestinal release and bioavailability improvement, effectively preventing and improving osteoarthritis.
Patent Information
- Application Number
- CN202410929019.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-11
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art is difficult to effectively target the intestine to release hydrophobic phytochemicals, especially in the process of gastric digestion, resulting in low bioavailability and failure to effectively protect the structure of non-denaturated type II collagen.
By forming a non-denaturated type II collagen-hydrophobic phytochemical-chondroitin sulfate ternary complex, the electrostatic interaction is used to form a tight complex under acidic conditions, improving the solubility and stability of hydrophobic phytochemicals, and Reduce degradation during gastric digestion and prolong intestinal retention time.
The targeted intestinal release of hydrophobic phytochemicals is achieved, which reduces losses and degradation during gastric digestion, improves bioavailability, and shows free radical scavenging activity during intestinal release, effectively preventing and improving bones arthritis.
Smart Images

Figure CN118903451A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of health products, and in particular relates to a non-denatured type II collagen-hydrophobic phytochemical substance-chondroitin sulfate complex for targeted intestinal release and a preparation method thereof. Background Art
[0002] Osteoarthritis is a degenerative disease characterized by wear, destruction and loss of articular cartilage, accompanied by bone hyperplasia around joints, mainly manifested as joint pain and dysfunction, and its incidence rate ranks among the top 10 non-communicable diseases. The pathogenesis of osteoarthritis is not yet fully understood, among which the vicious cycle formed by autoimmunity, inflammation and oxidative stress response cannot be ignored in the course of the disease.
[0003] A large number of animal and clinical trials have shown that oral non-denatured type II collagen can significantly reduce the incidence of osteoarthritis or relieve symptoms such as wear of articular cartilage, and long-term consumption will not cause side effects caused by taking drugs. After entering the intestine, oral non-denatured type II collagen stimulates intestinal-associated lymphoid tissue, induces immune tolerance, and thus inhibits autoimmunity and local inflammatory reactions in joints. Chondroitin sulfate, an anionic polysaccharide with a high content in human and animal cartilage, also has a certain improvement effect on arthritis, has the effect of analgesia and promoting cartilage regeneration. In addition, many studies have shown that polyphenols with strong antioxidant and anti-inflammatory properties can prevent oxidative stress-related diseases and inflammatory diseases, and also have osteoarthritis inhibitory activity. For example: astaxanthin, baicalin, quercetin, curcumin, morin, etc. have been verified in in vitro and in vivo models of osteoarthritis. However, these polyphenols are highly hydrophobic, poorly soluble in water, and unstable, resulting in low oral absorption rate and bioavailability. The small intestine is the main site of absorption of most hydrophobic phytochemicals, and the strongly acidic environment in the gastric cavity easily changes the structure and permeability of the carrier, which is also a challenge to the delivery of hydrophobic phytochemicals, making it impossible to safely transport them to the absorption site. Therefore, reducing gastric loss and prolonging intestinal retention time are also particularly important for the delivery of these hydrophobic phytochemicals. The bioavailability of hydrophobic phytochemicals can be improved by encapsulating them in delivery systems, including solid dispersions, complexes with cyclodextrins, copolymer micelles, polymer nanoparticles, lipid-based nanoparticles, liposomes, and microemulsions. The main purpose of these delivery systems is to improve the bioaccessibility, stability, tissue distribution, and elimination half-life of hydrophobic phytochemicals.
[0004] A Chinese patent (application number: CN202011102015.0) applies for a composition for preventing and / or treating osteoarthritis, which comprises modified citrus pectin, curcumin, denatured collagen II, collagen XIV, boswellic acid, astaxanthin and hyaluronic acid. However, the composition uses denatured type II collagen, and only physically mixes different active ingredients, without considering the poor solubility and stability, short half-life, and low bioavailability of hydrophobic phytochemicals. Therefore, finding a structure that can target the intestinal tract to release hydrophobic phytochemicals while protecting non-denatured type II collagen is an urgent problem to be solved in this field.
[0005] Proteins, polysaccharides, and polyphenols are natural ingredients with different functional properties. These three ingredients can form protein and / or polysaccharide and / or polyphenol complexes through covalent or noncovalent interactions to produce new multifunctional ingredients with new or improved properties. Studies have shown that protein-polysaccharide, protein-polyphenol, and protein-polysaccharide-polyphenol complexes can be used to make colloidal systems to encapsulate, protect, and deliver bioactive ingredients such as vitamins, nutraceuticals, and probiotics in bioavailable forms. Protein-polyphenol-polysaccharide complex ternary complexes are usually formed by changing the solvent quality, pH, ionic strength, and / or temperature of the mixed system. Among them, pH has an important effect on the formation and properties of polysaccharide-protein complexes, which is mainly the effect on intermolecular electrostatic interactions. In addition, a study reported that hydrophobic interactions are the main interactions involved in the formation of wheat gliadin and quercetin complexes under acidic pH conditions. However, complexes that simultaneously target the intestinal tract with non-denatured type II collagen protein, hydrophobic phytochemicals, and chondroitin sulfate with osteoarthritis-improving activity have not been reported. Summary of the invention
[0006] In order to overcome the shortcomings of the prior art, the purpose of the present invention is to provide a non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate complex with targeted intestinal release and a preparation method thereof.
[0007] The purpose of the present invention is achieved by at least one of the following technical solutions.
[0008] The invention provides a non-denatured type II collagen-hydrophobic phytochemical substance-chondroitin sulfate ternary complex for targeted intestinal release, the raw materials of which include non-denatured type II collagen, hydrophobic phytochemical substance and chondroitin sulfate.
[0009] The present invention provides a non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate ternary complex for targeted intestinal release, which comprises the following raw materials in parts by mass:
[0010] 10-100 parts of non-denatured type II collagen;
[0011] 1-50 parts of hydrophobic phytochemicals;
[0012] Chondroitin sulfate 10-100 parts.
[0013] The present invention firstly adopts non-denatured type II collagen to load hydrophobic phytochemicals to improve its solubility, stability and bioaccessibility; then forms a non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate ternary complex through the electrostatic association of chondroitin sulfate and non-denatured type II collagen, thereby reducing the degradation of non-denatured type II collagen and hydrophobic phytochemicals during gastric digestion, targeting intestinal release and prolonging intestinal retention time.
[0014] In the present invention, hydrophobic phytochemicals include astaxanthin, curcumin, quercetin, wogonin, morin, etc., which have antioxidant, anti-inflammatory, immune and osteoarthritis inhibitory activities, are poorly soluble in water, unstable, and have low bioaccessibility, and can form a complex with non-denatured type II collagen through hydrophobic interactions. The chondroitin sulfate of the present invention can form a tight complex with non-denatured type II collagen through electrostatic interactions under acidic conditions. The ternary complex formed by the present invention can be released in a targeted manner in the intestine, reducing the damage of non-denatured type II collagen and hydrophobic phytochemicals during gastric digestion.
[0015] The non-denatured type II collagen of the present invention is reported to have an effect of improving osteoarthritis.
[0016] The present invention provides a non-denatured type II collagen-hydrophobic phytochemical substance-chondroitin sulfate ternary complex for targeted intestinal release and a preparation method thereof, comprising the following steps:
[0017] (1) Prepare a non-denatured type II collagen solution and adjust the pH value of the solution to acidic.
[0018] (2) Add solid powder of hydrophobic phytochemical substances, stir thoroughly, and centrifuge to obtain supernatant.
[0019] (3) Add high concentration chondroitin sulfate solution, stir evenly, let stand, and centrifuge to obtain the precipitate.
[0020] (4) freeze-drying and pulverizing to obtain a non-denatured type II collagen-hydrophobic phytochemical substance-chondroitin sulfate ternary complex powder.
[0021] Furthermore, in step (1), the pH value of the non-denatured type II collagen solution is in the range of 2.0-4.0, and the concentration range is in the range of 1-10 mg / mL.
[0022] Furthermore, in step (2), the hydrophobic phytochemicals include one or more of astaxanthin, curcumin, quercetin, wogonin, and morin.
[0023] Furthermore, in step (2), the amount of the hydrophobic phytochemical added is 0.1-1‰ (w / w) of the final solution concentration.
[0024] Furthermore, in step (2), the stirring speed is 300-700 rpm, the stirring temperature is 20-25° C., and the stirring time is 3-8 h.
[0025] Furthermore, in step (2), the centrifugal speed is 5000-8000×g, and the time is 10-20 min.
[0026] Furthermore, in step (3), the concentration of the chondroitin sulfate solution is 50-500 mg / mL.
[0027] Furthermore, in step (3), the volume ratio of the chondroitin sulfate solution to the non-denatured type II collagen solution is (0.01-0.1):1.
[0028] Furthermore, in step (3), the standing time is 1-5 hours.
[0029] Furthermore, in step (3), the centrifugal speed is 2000-4000×g, and the time is 10-20 min.
[0030] Furthermore, in step (4), the freeze-drying time is 24-48 hours.
[0031] The present invention also provides a non-denatured type II collagen-hydrophobic phytochemical substance-chondroitin sulfate ternary complex prepared by the preparation method.
[0032] Furthermore, the content of non-denatured type II collagen in the complex is >40.0%, and the content of hydrophobic phytochemicals is >10 μg / mg.
[0033] The present invention also conducts an in vitro simulated gastrointestinal digestion research test on the above non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate ternary complex. The test includes:
[0034] The non-denatured type II collagen-hydrophobic phytochemical binary complex prepared in Comparative Examples 4 and 5 of the present invention, and the non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate ternary complex prepared in Example 1, Example 2, and Example 3 were added to the simulated gastric digestive fluid preheated at 37°C at a ratio of 1:1 (v / v), and adjusted to pH 1.2 with 1 mol / L HCl. After the pH was stable for at least 5 minutes, CaCl2 (H2O)2 solution and porcine pepsin were added, and the mixed solution was placed in a 37°C constant temperature shaker for incubation for 0.5h and 1.0h. The samples were taken out and immediately placed in a refrigerator to terminate the action of the enzyme for testing. Or add the simulated intestinal digestion solution preheated at 37°C to the above gastric digestion product at a ratio of 1:1 (v / v), adjust the system to pH 7.0 with 1 mol / L NaOH, add bile, CaCl2(H2O)2 solution, and pancreatic enzyme, and incubate the mixture in a 37°C constant temperature shaker for 0.5h, 1h, 2h, 4h, and 6h. After taking out the sample, immediately put it in a refrigerator to terminate the action of the enzyme for testing. The samples in the above digestion process were subjected to the determination of the release rate of hydrophobic phytochemical substances, the determination of the free radical scavenging rate, and the structural changes of type II collagen using circular dichroism spectroscopy.
[0035] The non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate ternary complex of the present invention is almost not digested in the extremely acidic gastric environment, and the hydrophobic phytochemical is protected in the complex without obvious release, but is gradually released during the subsequent intestinal digestion process and shows free radical scavenging activity. However, after the non-denatured type II collagen-hydrophobic phytochemical binary complex undergoes gastric digestion, the structure of the non-denatured type II collagen is severely degraded, and the hydrophobic phytochemical is completely exposed to the gastric digestive juice in the early stage of gastric digestion, precipitated with the degradation of the non-denatured type II collagen, and the free radical scavenging activity is reduced, and then it is dissolved in the intestinal digestion stage and exerts free radical scavenging activity.
[0036] Compared with the prior art, the present invention has the following advantages and beneficial effects:
[0037] 1. The technology of the present invention uses non-denatured type II collagen to load hydrophobic phytochemicals under acidic conditions, thereby avoiding the loss of hydrophobic phytochemicals that are easily degraded under neutral and alkaline conditions.
[0038] 2. The preparation method of the present invention is simple and easy to implement. In the process of loading the hydrophobic phytochemicals, no organic reagents such as cyclohexane, ethanol, and acetone are used, which has little hazard and reduces environmental pollution.
[0039] 3. The content of non-denatured type II collagen in the non-denatured type II collagen-hydrophobic phytochemical substance-chondroitin sulfate ternary complex obtained by the preparation method of the present invention is >40.0%, and the content of hydrophobic phytochemical substance is >10 μg / mg.
[0040] 4. The ternary complex obtained by the preparation method of the present invention can be released in a targeted manner in the intestine, reduce the degradation and loss of non-denatured type II collagen and hydrophobic phytochemicals during gastric digestion, and increase intestinal retention and elimination half-life.
[0041] 5. The ternary complex obtained by the preparation method of the present invention can not only suppress autoimmune response by inducing immune tolerance through non-denatured type II collagen, but also prevent and improve osteoarthritis by reducing oxidative stress and inflammatory response through hydrophobic phytochemicals with antioxidant and anti-inflammatory activities. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] Figure 1 This is a bar graph showing the hydrophobic phytochemical loading of the composites prepared from Example 1, Example 2, Example 3, Example 4, Example 5, Comparative Example 1, Comparative Example 2, Comparative Example 3, Comparative Example 4, and Comparative Example 5.
[0043] Figure 2 The X-ray diffraction (XRD) diagrams of the composites prepared in Example 1, Example 2, Example 3, Comparative Example 4 and Comparative Example 5 are shown.
[0044] Figure 3 The differential scanning calorimetry (DSC) diagrams of the composites prepared in Example 1, Example 2, Example 3, Comparative Example 4 and Comparative Example 5 are shown.
[0045] Figure 4 It is a line graph of the release rate of hydrophobic phytochemical substances of the complexes prepared in Example 1, Example 2, Example 3, Comparative Example 4 and Comparative Example 5 during gastrointestinal digestion.
[0046] Figure 5 It is a line graph showing the changes in free radical scavenging rates of the complexes prepared in Example 1, Example 2, Example 3, Comparative Example 4 and Comparative Example 5 in the digestive juice during gastrointestinal digestion.
[0047] Figure 6 This is a line graph showing the change in ellipticity of the positive absorption peak of the circular dichroism spectrum of the non-denatured type II collagen of the composites prepared in Example 1, Example 2, Example 3, Comparative Example 4 and Comparative Example 5 during gastrointestinal digestion.
[0048] Table 1 shows the denaturation temperatures and enthalpy change values of the composites prepared in Example 1, Example 2, Example 3, Comparative Example 4 and Comparative Example 5. DETAILED DESCRIPTION
[0049] The specific implementation of the present invention is further described below in conjunction with examples, but the implementation and protection of the present invention are not limited thereto. It should be noted that if there are processes that are not particularly described in detail below, they can be implemented or understood by those skilled in the art with reference to the prior art. If the manufacturer of the reagents or instruments used is not indicated, they are deemed to be conventional products that can be purchased commercially.
[0050] The weight (mass) parts used in the following embodiments and comparative examples are, for example, weight units may be grams, kilograms, etc., or any other commonly used amount in the art.
[0051] Comparative Example 1
[0052] A non-denatured type II collagen-hydrophobic phytochemical binary complex comprises the following steps:
[0053] 1. Weigh 50 mg of non-denatured type II collagen powder, dissolve it in 10 mL of deionized water, and adjust the pH value of the solution to 7.0 with 2 M HCl.
[0054] 2. Weigh 10 mg of quercetin powder and add it to the above non-denatured type II collagen solution while stirring. Place the mixture in a multi-channel magnetic stirrer and stir at 500 rpm and 20°C for 5 h.
[0055] 3. After stirring, centrifuge at 5000×g for 15 minutes and take the supernatant.
[0056] 4. Freeze-dry for 24 hours to obtain a non-denatured type II collagen-hydrophobic phytochemical binary complex solid.
[0057] Comparative Example 2
[0058] A non-denatured type II collagen-hydrophobic phytochemical binary complex comprises the following steps:
[0059] 1. Weigh 60 mg of non-denatured type II collagen powder, dissolve it in 10 mL of deionized water, and adjust the pH of the solution to 6.0 with 2 M HCl.
[0060] 2. Weigh 1 mg of wogonin powder and add it to the above non-denatured type II collagen solution while stirring. Place the mixture in a multi-channel magnetic stirrer and stir at 700 rpm and 25°C for 8 h.
[0061] 3. After stirring, centrifuge at 5000×g for 15 minutes and take the supernatant.
[0062] 4. Freeze-dry for 48 hours to obtain a non-denatured type II collagen-hydrophobic phytochemical binary complex solid.
[0063] Comparative Example 3
[0064] A non-denatured type II collagen-hydrophobic phytochemical binary complex comprises the following steps:
[0065] 1. Weigh 100 mg of non-denatured type II collagen powder, dissolve it in 10 mL of deionized water, and adjust the pH value of the solution to 6.5 with 2 M HCl.
[0066] 2. Weigh 5 mg of mulberry pigment powder and add it to the above non-denatured type II collagen solution while stirring. Place the mixture in a multi-channel magnetic stirrer and stir at 600 rpm and 25°C for 6 hours.
[0067] 3. After stirring, centrifuge at 6000×g for 10 minutes and take the supernatant.
[0068] 4. Freeze-dry for 48 hours to obtain a non-denatured type II collagen-hydrophobic phytochemical binary complex solid.
[0069] Comparative Example 4
[0070] A non-denatured type II collagen-hydrophobic phytochemical binary complex comprises the following steps:
[0071] 1. Weigh 40 mg of non-denatured type II collagen powder, dissolve it in 10 mL of deionized water, and adjust the pH value of the solution to 3.0 with 2 M HCl.
[0072] 2. Weigh 3 mg of curcumin powder and add it to the above non-denatured type II collagen solution while stirring. Place the mixture in a multi-channel magnetic stirrer and stir at 400 rpm and 25°C for 6 h.
[0073] 3. After stirring, centrifuge at 8000×g for 15 minutes and take the supernatant.
[0074] 4. Freeze-dry for 36 hours to obtain a non-denatured type II collagen-hydrophobic phytochemical binary complex solid.
[0075] Comparative Example 5
[0076] A non-denatured type II collagen-hydrophobic phytochemical binary complex comprises the following steps:
[0077] 1. Weigh 20 mg of non-denatured type II collagen powder, dissolve it in 10 mL of deionized water, and adjust the pH of the solution to 3.5 with 2 M HCl.
[0078] 2. Weigh 4 mg of astaxanthin powder and add it to the above non-denatured type II collagen solution while stirring. Place the mixture in a multi-channel magnetic stirrer and stir at 500 rpm and 20°C for 5 hours.
[0079] 3. After stirring, centrifuge at 8000×g for 10 minutes and take the supernatant.
[0080] 4. Freeze-dry for 24 hours to obtain a non-denatured type II collagen-hydrophobic phytochemical binary complex solid.
[0081] Example 1
[0082] A non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate ternary complex comprises the following steps:
[0083] 1. Weigh 50 mg of non-denatured type II collagen powder, dissolve it in 10 mL of deionized water, and adjust the pH value of the solution to 3.0 with 2 M HCl.
[0084] 2. Weigh 5 mg of curcumin powder and add it to the above non-denatured type II collagen solution while stirring. Place the mixture in a multi-channel magnetic stirrer and stir at 500 rpm and 20°C for 4 h.
[0085] 3. After stirring, centrifuge at 6000×g for 15 minutes and take the supernatant.
[0086] 4. Prepare 500 mg / mL chondroitin sulfate solution, add it to the supernatant of step 3 at a volume ratio of 0.01:1 while stirring, and let it stand for 2 hours.
[0087] 5. After standing, centrifuge at 3000×g for 15 minutes to collect the precipitate.
[0088] 6. Freeze-dry for 48 hours to obtain a non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate ternary complex powder.
[0089] Example 2
[0090] A non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate ternary complex comprises the following steps:
[0091] 1. Weigh 10 mg of non-denatured type II collagen powder, dissolve it in 10 mL of deionized water, and adjust the pH of the solution to 2.0 with 2 M HCl.
[0092] 2. Weigh 3 mg of quercetin powder and add it to the above non-denatured type II collagen solution while stirring. Place the mixture in a multi-channel magnetic stirrer and stir at 300 rpm and 25°C for 3 h.
[0093] 3. After stirring, centrifuge at 6000×g for 15 minutes and take the supernatant.
[0094] 4. Prepare 50 mg / mL chondroitin sulfate solution, add it to the supernatant of step 3 at a volume ratio of 0.1:1 while stirring, and let it stand for 1 hour.
[0095] 5. After standing, centrifuge at 4000×g for 10 min to collect the precipitate.
[0096] 6. Freeze-dry for 36 hours to obtain non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate ternary complex powder.
[0097] Example 3
[0098] A non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate ternary complex comprises the following steps:
[0099] 1. Weigh 40 mg of non-denatured type II collagen powder, dissolve it in 10 mL of deionized water, and adjust the pH of the solution to 2.5 with 2 M HCl.
[0100] 2. Weigh 6 mg of mulberry pigment powder and add it to the above non-denatured type II collagen solution while stirring. Place the mixture in a multi-channel magnetic stirrer and stir at 400 rpm and 25°C for 4 h.
[0101] 3. After stirring, centrifuge at 8000×g for 20 minutes and take the supernatant.
[0102] 4. Prepare 200 mg / mL chondroitin sulfate solution, add it to the supernatant of step 3 at a volume ratio of 0.06:1 while stirring, and let it stand for 3 hours.
[0103] 5. After standing, centrifuge at 2000×g for 20 minutes to collect the precipitate.
[0104] 6. Freeze-dry for 48 hours to obtain a non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate ternary complex powder.
[0105] Example 4
[0106] A non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate ternary complex comprises the following steps:
[0107] 1. Weigh 60 mg of non-denatured type II collagen powder, dissolve it in 10 mL of deionized water, and adjust the pH value of the solution to 3.5 with 2 M HCl.
[0108] 2. Weigh 10 mg of astaxanthin powder and add it to the above non-denatured type II collagen solution while stirring. Place the mixture in a multi-channel magnetic stirrer and stir at 600 rpm and 25°C for 5 hours.
[0109] 3. After stirring, centrifuge at 8000×g for 20 minutes and take the supernatant.
[0110] 4. Prepare 400 mg / mL chondroitin sulfate solution, add it to the supernatant of step 3 at a volume ratio of 0.08:1 while stirring, and let it stand for 4 hours.
[0111] 5. After standing, centrifuge at 5000×g for 10 min to collect the precipitate.
[0112] 6. Freeze-dry for 24 hours to obtain non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate ternary complex powder.
[0113] Example 5
[0114] A non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate ternary complex comprises the following steps:
[0115] 1. Weigh 30 mg of non-denatured type II collagen powder, dissolve it in 10 mL of deionized water, and adjust the pH value of the solution to 4.0 with 2 M HCl.
[0116] 2. Weigh 1 mg of wogonin powder and add it to the above non-denatured type II collagen solution while stirring. Place the mixture in a multi-channel magnetic stirrer and stir at 300 rpm and 20°C for 8 h.
[0117] 3. After stirring, centrifuge at 6000×g for 20 minutes and take the supernatant.
[0118] 4. Prepare 300 mg / mL chondroitin sulfate solution, add it to the supernatant of step 3 at a volume ratio of 0.06:1 while stirring, and let it stand for 5 hours.
[0119] 5. After standing, centrifuge at 3000×g for 15 minutes to collect the precipitate.
[0120] 6. Freeze-dry for 48 hours to obtain a non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate ternary complex powder.
[0121] The loading of hydrophobic phytochemicals in the composites was determined after freeze drying. Figure 1As shown. The hydrophobic phytochemical loading of the non-denatured type II collagen-hydrophobic phytochemical binary complex obtained by the preparation methods of Comparative Examples 4 and 5 (24.37 and 23.64 μg / mg, respectively) is significantly higher than the complexes prepared under neutral conditions in Comparative Examples 1, 2 and 3 (all less than 2 μg / mg). The hydrophobic phytochemical loading of the non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate ternary complex obtained by the preparation methods of Examples 1, 2, 3, 4 and 5 (12.63, 11.86, 13.05, 11.2 and 10.29 μg / mg, respectively) is about twice as low as the loading of the non-denatured type II collagen-hydrophobic phytochemical binary complex obtained by the preparation methods of Comparative Examples 4 and 5, because the addition of chondroitin sulfate increases the overall mass of the complex.
[0122] The crystal structures of the composites prepared in Example 1, Example 2, Example 3, Comparative Example 4 and Comparative Example 5 were analyzed by X-ray diffraction. Figure 2 As shown. The X-ray diffraction patterns of Comparative Examples 4 and 5 show two diffraction peaks, and the presence of the diffraction peaks reflects the existence of an ordered structure in the non-denatured type II collagen molecule. The two diffraction peaks are: a sharp peak near 7.3°, representing the inherent lattice of the molecule and the triple helix structure content of non-denatured type II collagen; a broad peak near 20.5°, which is the diffuse scattering caused by the amorphous region of the non-denatured type II collagen-hydrophobic phytochemical-binary complex. The X-ray diffraction patterns of Example 1, Example 2 and Example 3 also show two diffraction peaks: the first peak is located near 8.3°, and the position of the diffraction peak has changed compared to Comparative Examples 4 and 5, which may be due to the coating effect of chondroitin sulfate on non-denatured type II collagen. The position of the second broad diffraction peak is located near 20.5°, which is close to the peak position of Comparative Examples 4 and 5, but the peak area increases, indicating that the crystallinity of the non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate ternary complex may increase. The results of the above X-ray diffraction peaks indicate that the hydrophobic phytochemicals originally in a crystalline state have their crystals reduced in size and transformed into an amorphous state after being complexed with non-denatured type II collagen-chondroitin sulfate or non-denatured type II collagen.
[0123] In order to compare the thermal stability of the composites prepared in Example 1, Example 2, Example 3 and Comparative Example 4, Comparative Example 5, their denaturation temperatures and enthalpy change values were measured by differential scanning calorimetry. The results are as follows: Figure 3 As shown in Table 1. Example 4 and Comparative Example 5 have a first smaller endothermic peak at 103-105°C, and the enthalpy change value is 23-26 J / g -1This may be the endothermic peak caused by the dehydration of non-denatured type II collagen and the destruction of the triple helix structure in the complex; a second larger endothermic peak appears at 171-175℃, with an enthalpy change of 158-163J / g -1 This may be the melting peak of the crystalline region corresponding to the destruction of the crystalline structure of the binary composite during the thermal shrinkage process. In contrast, the first endothermic peak of Example 1, Example 2, and Example 3 appears at 117-119°C, and the enthalpy change value is 18-19 J / g -1 , the denaturation temperature is significantly higher than that of Comparative Example 4 and Comparative Example 5. This may be due to the non-covalent interaction between chondroitin sulfate and non-denatured type II collagen, which makes the ternary complex structure more compact and enhances the affinity of the complex for water molecules, thereby increasing the temperature of water loss and denaturation of the triple helix structure. In addition, the enthalpy change value of the embodiment is lower than that of the comparative example, which may be related to the lower water content in the ternary complex. The second endothermic peak of Example 1, Example 2, and Example 3 appears at 175-177°C, and the enthalpy change value is 152-169J / g -1 , which is similar to the results of the comparative example, indicating that the addition of chondroitin sulfate has little effect on the crystalline melting of the composite.
[0124] The release rate of hydrophobic phytochemicals in the composites during simulated gastrointestinal digestion was determined. Figure 4 As shown. The non-denatured type II collagen-hydrophobic phytochemical binary complex obtained by the preparation methods of Comparative Examples 4 and 5 is in a dissolved state at the initial stage of gastric digestion, that is, it is fully exposed to the acidic gastric digestive juice, and the solubility gradually decreases during gastric digestion, which may be related to the degradation of non-denatured type II collagen during gastric digestion. Subsequently, it mixes with bile acid to form micelles during intestinal digestion and redissolves and releases. The hydrophobic phytochemicals of the non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate ternary complex obtained by the preparation methods of Examples 1, 2, and 3 are hardly released during gastric digestion. This is because non-denatured type II collagen and chondroitin sulfate carry opposite charges under the acidic conditions of gastric juice, and the two associate to form an insoluble complex that resists digestion by pepsin. After entering the intestinal digestion stage, the pH value becomes neutral, and the non-denatured type II collagen and chondroitin sulfate carry the same charge. Therefore, as the intestinal digestion time increases, the ternary complex gradually dissolves, and the hydrophobic phytochemicals are slowly released into the intestinal fluid to form micelles with bile acid.
[0125] The free radical scavenging activity of the hydrophobic phytochemicals in the complex was further determined during simulated gastrointestinal digestion. Figure 5As shown. The free radical scavenging activity of the non-denatured type II collagen-hydrophobic phytochemical binary complex obtained by the preparation methods of comparative examples 4 and 5 was about 60% in the early stage of gastric digestion, and decreased to a certain extent during gastric digestion, which may be related to the reduced solubility of hydrophobic phytochemicals and the release of some antioxidant peptides by hydrolysis of non-denatured type II collagen. During intestinal digestion, as the precipitated hydrophobic phytochemicals were redissolved and released, the free radical scavenging activity increased, and the free radical scavenging activity increased to 81%-83% after 6 hours of intestinal digestion. The hydrophobic phytochemicals of the non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate ternary complex obtained by the preparation methods of Examples 1, 2, and 3 were not released during gastric digestion, and the free radical scavenging activity was about 10%. After entering the intestinal digestion stage, its free radical scavenging activity increased with the release of hydrophobic phytochemicals, and it can also increase to 77%-85% after 6 hours of intestinal digestion.
[0126] The structure of non-denatured type II collagen in the composite was determined during simulated gastrointestinal digestion. Figure 6 As shown. The intensity of the positive absorption peak in the circular dichroism spectrum can reflect the integrity of the triple helix structure of type II collagen. If the triple helix structure is completely destroyed, the positive absorption peak may disappear. The triple helix structure of non-denatured type II collagen-hydrophobic phytochemical binary complex obtained by the preparation methods of comparative examples 4 and 5 is severely damaged during gastric digestion. After 1h of gastric digestion, the ellipticity at 222nm (positive absorption peak) in the circular dichroism spectrum decreased from 8.2-8.4 to 2.9-3.2. After entering the intestinal digestion stage, the triple helix structure of non-denatured type II collagen is quickly completely degraded, that is, the ellipticity at 222nm is reduced to 0. In contrast, the non-denatured type II collagen of the non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate ternary complex obtained by the preparation methods of Examples 1, 2, and 3 is tightly combined with chondroitin sulfate to form an insoluble complex, which is hardly released during gastric digestion. After entering the intestinal digestion stage, as the ternary complex dissolves, non-denatured type II collagen is released, and its triple helix structure is partially degraded under the action of bile acid and trypsin, etc. In addition, as the intestinal digestion time increases, the degradation rate of the triple helix structure slows down, and its ellipticity (2.5-4.3) at 222nm is significantly higher than that of the non-denatured type II collagen-hydrophobic phytochemical binary complex.
[0127] Table 1 Denaturation temperature and enthalpy change of samples prepared by the methods of Examples 1, 2, 3 and Comparative Examples 4 and 5
[0128]
[0129] The above embodiments are only preferred implementation modes of the present invention and are only used to explain the present invention rather than to limit the present invention. Any changes, substitutions, modifications, etc. made by those skilled in the art without departing from the spirit of the present invention should fall within the scope of protection of the present invention.
Claims
1. A non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate complex for targeted intestinal release, It is characterized in that The raw materials of the non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate ternary complex include the following raw materials in parts by mass: 10-100 parts of non-denatured type II collagen; 1-50 parts of hydrophobic phytochemicals; Chondroitin sulfate 10-100 parts.
2. The non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate complex for targeted intestinal release according to claim 1, It is characterized in that The hydrophobic phytochemicals include astaxanthin, curcumin, quercetin, wogonin or morin.
3. The non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate complex for targeted intestinal release according to claim 1, It is characterized in that The composite has a non-denatured type II collagen content of >40.0% and a hydrophobic phytochemical content of >10 μg / mg.
4. A method for preparing the intestinal targeted release non-denatured type II collagen-hydrophobic phytochemical substance-chondroitin sulfate complex according to any one of claims 1 to 3, It is characterized in that The steps include: (1) preparing a non-denatured type II collagen solution and adjusting the pH value of the solution to acidic; (2) adding solid powder of hydrophobic phytochemical substances, stirring thoroughly, and centrifuging to obtain supernatant; (3) adding a high concentration of chondroitin sulfate solution to the supernatant, stirring evenly, letting it stand, and centrifuging to obtain a precipitate; (4) freeze-drying and pulverizing to obtain a non-denatured type II collagen-hydrophobic phytochemical substance-chondroitin sulfate ternary complex powder.
5. The method for preparing the intestinal targeted release non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate complex according to claim 4, It is characterized in that In step (1), the pH value of the non-denatured type II collagen solution is 2.0-4.0, and the concentration is 1-10 mg / mL.
6. The method for preparing the intestinal targeted release non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate complex according to claim 4, It is characterized in that In step (2), the amount of the hydrophobic phytochemical added is 0.1-1‰ (w / w) of the final solution concentration.
7. The method for preparing the intestinal targeted release non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate complex according to claim 4, It is characterized in that In step (2), the stirring speed is 300-700 rpm, the stirring temperature is 20-25° C., and the stirring time is 3-8 h; The centrifugal speed is 5000-8000×g, and the time is 10-20 min.
8. The method for preparing the intestinal targeted release non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate complex according to claim 4, It is characterized in that In step (3), the concentration of the chondroitin sulfate solution is 50-500 mg / mL; The volume ratio of the chondroitin sulfate solution to the non-denatured type II collagen solution is (0.01-0.1):
1.
9. The method for preparing the intestinal targeted release non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate complex according to claim 4, It is characterized in that In step (3), the standing time is 1-5h; The centrifugal speed is 2000-4000×g, and the time is 10-20 min.
10. The method for preparing the intestinal targeted release non-denatured type II collagen-hydrophobic phytochemical-chondroitin sulfate complex according to claim 4, It is characterized in that In step (4), the freeze-drying time is 24-48 hours.
Citation Information
Cited By
Composite nutritional composition beneficial to improvement of joint function of sports people and application of composite nutritional composition
CN120661633A
A compound nutritional composition beneficial for joint function improvement of sports population and application thereof
CN120661633B
Composition for improving and / or treating exercise-induced osteoarthritis and preparation method and application thereof
CN121337962A
Compositions for improving and / or treating exercise-induced osteoarthritis and methods of making and using the same
CN121337962B
